Darolutamide
- Generic Name
- Darolutamide
- Brand Names
- Nubeqa
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN6O2
- CAS Number
- 1297538-32-9
- Unique Ingredient Identifier
- X05U0N2RCO
- Background
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patient...
- Indication
Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
- Associated Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- -
Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 132
- Registration Number
- NCT04335682
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Trans Tasman Radiation Oncology Group
- Target Recruit Count
- 70
- Registration Number
- NCT04319783
- Locations
- 🇦🇺
Icon Cancer Centre Epworth, Richmond, Victoria, Australia
🇦🇺Peter MacCallum Cancer Centre, Bendigo, Bendigo, Victoria, Australia
🇸🇬National Cancer Centre Singapore, Singapore, Singapore
Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 208
- Registration Number
- NCT04176081
- Locations
- 🇨🇦
UHN Princess Margaret Hospital, Toronto, Ontario, Canada
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2019-10-23
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 1100
- Registration Number
- NCT04136353
- Locations
- 🇨🇦
Regional Health Authority B, Zone 2 Saint John Regional Hospital, Saint John, New Brunswick, Canada
🇨🇦Ottawa Hospital Research Institute, Toronto, Ontario, Canada
🇨🇦Odette Cancer Centre - Sunnybrook Hospital, Toronto, Ontario, Canada
INTREPId (INTermediate Risk Erection PreservatIon Trial)
- Conditions
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 234
- Registration Number
- NCT04025372
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women Hospital, Boston, Massachusetts, United States
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: Enzalutamide Oral CapsuleDrug: Niraparib plus Abiraterone acetate plus PrednisoneDrug: Capivasertib plus DocetaxelDrug: CarboplatinDrug: Abiraterone Oral TabletDrug: Cabazitaxel 60 mg Solution for InjectionDrug: ApalutamideDrug: DarolutamideDrug: Docetaxel Injectable SolutionDrug: Radium Chloride Ra-223
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 750
- Registration Number
- NCT03903835
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
🇧🇪OLV Ziekenhuis Aalst, Aalst, Belgium
🇧🇪AZ Groeninge, Kortrijk, Belgium
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAnatomic Stage IV Breast Cancer AJCC v8AnemiaAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveCastration-Resistant Prostate Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AbirateroneDrug: AfatinibBiological: BevacizumabDrug: BicalutamideProcedure: Biospecimen CollectionDrug: BortezomibDrug: CabazitaxelDrug: CabozantinibDrug: CapecitabineDrug: CarboplatinDrug: CelecoxibDrug: CobimetinibDrug: CopanlisibDrug: DabrafenibDrug: DacomitinibDrug: DarolutamideDrug: DasatinibDrug: DoxorubicinBiological: DurvalumabDrug: EnasidenibDrug: EntrectinibDrug: EnzalutamideDrug: ErlotinibDrug: EverolimusDrug: FluorouracilDrug: IdelalisibDrug: ImatinibBiological: IpilimumabDrug: LenvatinibDrug: LeucovorinDrug: LorlatinibDrug: LosartanDrug: Nab-paclitaxelDrug: NeratinibBiological: NivolumabDrug: OlaparibDrug: OxaliplatinDrug: PalbociclibDrug: PanobinostatBiological: PembrolizumabBiological: PertuzumabDrug: PonatinibOther: Quality-of-Life AssessmentDrug: RegorafenibDrug: RuxolitinibDrug: SirolimusDrug: SorafenibDrug: SunitinibDrug: TrametinibBiological: Trastuzumab EmtansineDrug: TretinoinDrug: VemurafenibDrug: VenetoclaxDrug: VismodegibDrug: Vorinostat
- First Posted Date
- 2019-03-18
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT03878524
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Study to Evaluate CCS1477 in Advanced Tumours
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- CellCentric Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT03568656
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸New York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States
Prostate Cancer Biomarker Enrichment and Treatment Selection
- Conditions
- Interventions
- First Posted Date
- 2017-12-28
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 200
- Registration Number
- NCT03385655
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Study on Androgen Receptor and Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 94
- Registration Number
- NCT03383679
- Locations
- 🇫🇷
Centre François Baclesse, Caen, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.